# Sources — Jesse Owens

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 5, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. The Ohio State University Libraries. “Jesse Owens: A Lasting Legend. Growing Up.” Supports his birth as James Cleveland (J.C.) Owens in Oakville, Alabama, on September 12, 1913, “the last of 10 children raised by Henry and Mary Emma Owens,” sharecroppers; the family’s move to Cleveland in the early 1920s after an older sister wrote home about jobs; the teacher who misheard “J.C.” as “Jesse”; his coach Charles Riley; and his national interscholastic records in 1933. https://library.osu.edu/jesse-owens-a-lasting-legend/growing-up
2. The Ohio State University Libraries. “Jesse Owens: A Lasting Legend. The Owens Family.” Supports his meeting Minnie Ruth Solomon at Fairmount Junior High School in 1930, their three daughters, the move in the early 1970s from Chicago to the Scottsdale area of Arizona, that “in late 1979, Owens, a lifetime smoker, was diagnosed with lung cancer,” his death “three months later on March 31, 1980 … at the age of 66,” and Ruth Owens’s death in 2001. https://library.osu.edu/jesse-owens-a-lasting-legend/the-owens-family
3. The Ohio State University Libraries. “Jesse Owens: A Lasting Legend. Owens and The Ohio State University.” Supports his exclusion from the only men’s dormitory “because of his race,” the boarding house, the High Street restaurants that would not serve Black students, his part-time work, the three world records at the Big Ten championships in May 1935, and the honorary doctorate. https://library.osu.edu/jesse-owens-a-lasting-legend/owens-and-the-ohio-state-university
4. The Ohio State University Libraries. “Jesse Owens: A Lasting Legend. Owens’ Legacy: a National Icon.” Supports the ticker-tape parade in New York in 1936; exhibition races against local sprinters and a horse; the dry-cleaning company founded in 1938, the personal bankruptcy in 1939, the taxes owed on income after the Games and the later failure to file returns; his public relations and speaking work and youth work; and his appointment to the U.S. Olympic Committee board in 1973. https://library.osu.edu/jesse-owens-a-lasting-legend/owens-legacy-a-national-icon
5. The Ohio State University Archives. Biographical file “Owens, Jesse” (part 2): scanned newspaper clippings (UPI, AP, the *Columbus Dispatch*, the *Ohio State Lantern* and others, 1979 to 1980s) and his own published account. Read by text extraction from the PDF. Supports: one of nine children of a cotton sharecropper; pneumonia at 7 from which he nearly died, with a brother and a sister dying in the epidemic, and his description of himself as “sickly, emaciated” and “poverty-stricken”; his work running a freight elevator at university; four gold medals at Berlin in the 100 and 200 meters, the relay and the long jump; racing a horse for $50 a night when “Blacks weren’t allowed in any pro sports then”; the Presidential Medal of Freedom in 1976; living in the Phoenix area since 1972; first admission in Chicago in December 1979 “after reporting shortage of breath,” and admission to Michael Reese Hospital on December 12, where “his illness was diagnosed as adenocarcinoma, a form of cancer doctors said is usually associated with heavy cigarette smoking. Doctors said Owens smoked about a pack a day”; “a pack-a-day smoker for the past 35 years”; chemotherapy for “cancer of the left lung,” transfer to University Hospital in Tucson and outpatient chemotherapy at the University of Arizona Cancer Center, with shortness of breath and trouble talking; “inoperable lung cancer”; hospital stays “off and on for the past three-and-a-half months”; and his death on March 31, 1980, at the University of Arizona Health Sciences Center in Tucson, with his wife at his side. https://library.osu.edu/documents/university-archives/biographical_files/Owens_Jesse_2.pdf
6. HISTMED Master Roster v3. Internal project source. Its entries were provisional and were not treated as independent corroboration.

## Clinical guidance

1. U.S. Preventive Services Task Force. “Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.” *JAMA* 2021;325(10):962–970 (PMID 33687470). Yearly low-dose CT for adults 50 to 80 with a 20 pack-year history who smoke now or quit within 15 years (grade B). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening
2. Mazzone PJ, et al. “Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.” *Chest* 2021;160(5):e427–e494 (PMID 34270968). Shared decision-making, tobacco treatment within screening programs, and nodule management. https://pubmed.ncbi.nlm.nih.gov/34270968/
3. American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS) v2022. Category 4X: a category 3 or 4 nodule with features that increase suspicion of malignancy. https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Reporting-and-Data-Systems/Lung-RADS
4. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026). Staging with PET-CT and brain MRI, pathologic mediastinal staging, broad biomarker testing with EGFR and ALK excluded before perioperative immunotherapy, nivolumab with platinum doublet chemotherapy before surgery for resectable disease, lobectomy with node dissection, surveillance, and smoking cessation. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450
5. Forde PM, et al. “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer” (CheckMate 816). *N Engl J Med* 2022;386(21):1973–1985 (PMID 35403841). Three cycles of nivolumab 360 mg with platinum doublet chemotherapy before surgery for stage IB to IIIA disease. https://pubmed.ncbi.nlm.nih.gov/35403841/
6. American College of Chest Physicians, *Diagnosis and management of lung cancer*, 3rd edition (*Chest* 2013;143(5 Suppl)): Silvestri GA, et al., methods for staging (PMID 23649440); Brunelli A, et al., physiologic evaluation before resection (PMID 23649437), under which predicted postoperative FEV1 and DLCO both above 60 percent mean low risk without further testing; and Howington JA, et al., treatment of stage I and II disease (PMID 23649443). https://pubmed.ncbi.nlm.nih.gov/23649440/, https://pubmed.ncbi.nlm.nih.gov/23649437/, https://pubmed.ncbi.nlm.nih.gov/23649443/
7. Schneider BJ, et al. “Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.” *J Clin Oncol* 2021;39(36):4073–4126 (PMID 34724392). Thyroid, liver and other monitoring, and the grading of thyroid dysfunction and pneumonitis. https://pubmed.ncbi.nlm.nih.gov/34724392/
8. Schneider BJ, et al. “Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline Summary.” *JCO Oncol Pract* 2020;16(2):83–86 (PMID 32045555). https://pubmed.ncbi.nlm.nih.gov/32045555/
9. U.S. Preventive Services Task Force. “Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions” (2021). Behavioral support with pharmacotherapy. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions
10. CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (Aether Forge, 2026): immune-related adverse event laboratory tests (TSH, liver tests, glucose, cortisol) before each infusion; smoking cessation, dyspnea and cough assessment and distress screening at every visit; pulmonary rehabilitation before and after resection; neuropathy checks after platinum; surveillance CT every six months for two to three years, then yearly low-dose CT; no routine PET-CT, brain MRI or circulating markers for surveillance; the CMS shared decision-making requirement for screening. https://patrickrutledge.github.io/topthirty/
11. Equity: Aldrich MC, et al. “Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers.” *JAMA Oncol* 2019;5(9):1318–1324 (PMID 31246249): the earlier criteria came from a trial population with only 4 percent African American smokers and missed many African American smokers who developed lung cancer. Navuluri N, et al. “Racial Disparities in Lung Cancer Screening Among Veterans, 2013 to 2021.” *JAMA Netw Open* 2023;6(6):e2318795 (PMID 37326987): 30.5 percent of referred Black veterans completed screening, against 41.3 percent of White veterans. Bach PB, et al. “Racial differences in the treatment of early-stage lung cancer.” *N Engl J Med* 1999;341(16):1198–1205 (PMID 10519898): the surgery rate was 12.7 percentage points lower for Black patients with resectable lung cancer, which largely explained their lower survival. https://pubmed.ncbi.nlm.nih.gov/31246249/, https://pubmed.ncbi.nlm.nih.gov/37326987/, https://pubmed.ncbi.nlm.nih.gov/10519898/
12. Preventive care: Centers for Medicare & Medicaid Services, Medicare Wellness Visits; the Medicare Preventive Services reference (Aether Forge, 2026); U.S. Preventive Services Task Force recommendations on colorectal cancer (2021), abdominal aortic aneurysm (2019), prostate cancer (2018), falls prevention (2024), hepatitis C (2020) and statin use (2022); Centers for Disease Control and Prevention, Adult Immunization Schedule by Age. https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/preventive-services/medicare-wellness-visits.html, https://patrickrutledge.github.io/preventative_services/, https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html

## Editorial resolutions

- **Recent-death rule.** He died in 1980, so the rule does not apply. The claims are still limited to what the fetched sources state.
- **Sources not used.** The *New York Times* obituary (blocked), Britannica (blocked), Olympics.com (timed out) and the Smithsonian pages could not be read, and William J. Baker’s biography was not read; none is cited. The four gold medals rest on the Ohio State University Libraries and the archival clippings. The accounts on secondary websites that his cancer was “extremely aggressive and drug-resistant” were not found in a reliable fetched source and are not claimed. The histology (adenocarcinoma), the side (left lung) and the word “inoperable” come from contemporary newspaper clippings in the Ohio State University Archives, read by text extraction from scans; the quoted phrases were checked against the extracted text.
- **Conflicts.** The Ohio State University Libraries say he was the last of ten children; the clippings and his own account say nine. Both are recorded in CLM-0001. One clipping gives his time of death as 5:40 a.m. and another as 3:40 a.m.; neither is used. The clippings place his home in Paradise Valley and the Phoenix area; the library says Scottsdale; the record says the Phoenix area.
- **Smoking history.** “A pack-a-day smoker for the past 35 years” gives about 35 pack-years, which the modern record uses; the age at which he started is not documented. The claim is marked sensitive.
- **Index age and dates.** The synthetic date of birth is September 12, 1960 (shift 47 years). The index visit on May 11, 2026 maps to May 11, 1979, when he was 65 and living in the Phoenix area, seven months before the documented admission in December 1979. All visits map to May to October 1979, within his lifetime and before his documented diagnosis. Index age 65 was chosen, rather than 66, so that a full course of care fits between the index date and November 1, 2026 while staying before the documented diagnosis; he turns 66 before the wellness visit. The visits are not a claim about his real care in 1979.
- **The teaching contrast.** His documented cancer was an inoperable adenocarcinoma of the left lung found after breathlessness began. The modern episode finds an adenocarcinoma of the left upper lobe by low-dose screening while it is still stage IIB and resectable, because he meets the 2021 USPSTF criteria. This is a teaching choice, not a claim about what screening could have done in his lifetime; low-dose CT screening did not exist then. The synthetic history that no clinician had offered him screening illustrates the documented under-offer of screening to Black smokers and is not a claim about his real care.
- **Presenting problem.** The Lung-RADS 4X nodule (R91.1) is the presenting finding at intake and is resolved at the diagnosis visit on May 26, 2026, when the adenocarcinoma (C34.12, both_with_link to the documented diagnosis) is recorded. He is asymptomatic apart from a long-standing smoker’s cough, so he is a screening candidate rather than a diagnostic patient; the intake documents show only the same-day screening CT and the plan.
- **Treatment choice.** Stage IIB (cT1c N1 M0) with no EGFR or ALK alteration: three cycles of nivolumab with carboplatin and pemetrexed before surgery (CheckMate 816) were chosen over surgery first followed by adjuvant therapy, because treatment before surgery gives a pathologic response to guide later decisions and the ability to start systemic therapy at once. Perioperative regimens that add immunotherapy after surgery are alternatives; after a major pathologic response with negative nodes the record has him choose surveillance after discussion. These choices are clinical judgment calls for review. KRAS G12C is recorded for use only if the cancer recurs.
- **Palliative care.** Specialist palliative care was not requested, because the cancer was treated with curative intent and caused no symptom burden; symptom, distress and mood screening at each visit and advance care planning at the wellness visit stand in its place. This is recorded as not indicated in the monitoring table.
- **Tobacco.** He smokes at intake and starts varenicline at the diagnosis visit, quitting on the day of cycle 1. Nicotine dependence (F17.210) is resolved at the visit after surgery and replaced by nicotine dependence in early remission (F17.211, both_with_link). F17 codes do not require a safety assessment, and every mood screen is below threshold.
- **Synthetic clinical picture.** All visits, results, imaging, pathology, stage, biomarkers (PD-L1 40 percent, KRAS G12C), doses (carboplatin 525 mg by the Calvert formula; pemetrexed 970 mg for a body surface area of 1.94 m2), the operation and its pathology (ypT1a N0, R0, 6 percent viable tumor), his height (178 cm) and weights are synthetic. Pulmonary function values are coded with the imaging category, as in other records; the DLCO percent predicted and the predicted postoperative values are in note text.
- **Sick visit.** A rhinovirus cold on day 13 of cycle 2 (J06.9), chosen because a new cough on a checkpoint inhibitor must be distinguished from immune-related pneumonitis and from neutropenic infection, which teaches the warning-sign pathway and insinuates no undocumented real diagnosis. The exposure is attributed to children at a youth club, not to any relative.
- **Annual wellness visit.** A subsequent annual wellness visit at 66 (HCPCS G0439 and CPT 99497 in plain text): influenza, COVID-19, RSV and the first zoster vaccines; PCV20 already given before treatment; abdominal aortic aneurysm screening met by the staging CT; lung cancer screening replaced by surveillance; a lipid panel ordered because of coronary calcification on the screening CT; and advance care planning with an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (diagnosis and consultation, cycle 2, after three cycles, and six weeks after surgery) are documented as focused visits on the NCCN guideline, the CMID lung cancer monograph, ASCO immune-related adverse event guidance, ACCP staging and physiologic evaluation guidance, and the USPSTF tobacco recommendation. Synthetic findings introduced: a grade 1 subclinical thyroiditis on nivolumab (TSH 6.8 with normal free T4 after three cycles, 4.6 six weeks after surgery, untreated), and the state after lobectomy (Z90.2). One protocol deviation is recorded instead of an invented result: the morning cortisol that the CMID schedule calls for before each immunotherapy infusion was not drawn at cycle 2 because the order set lacked it; no symptoms or signs of adrenal insufficiency; corrective action: cortisol added to the standing order set, drawn before surgery (12.9 mcg/dL, normal), closing the deviation.
- **Consultation.** The thoracic oncology referral and the consultation by Ngozi Halvorsen-Pierce, MD (a fictional consultant), on the diagnosis day, are **S**. The consultant answers the six referral questions in line with what the record shows afterwards: stage IIB on systematic EBUS staging; three cycles of nivolumab with carboplatin and pemetrexed, restaging and thoracoscopic lobectomy; EGFR and ALK excluded first; fitness for lobectomy from predicted postoperative values; varenicline; surveillance after a major pathologic response; and no specialist palliative care for now.
- **Equity.** The teaching objective, the intake plan and the consultation cite documented disparities: earlier screening criteria that missed many Black smokers, lower completion of screening by Black patients after referral, and lower rates of surgery for Black patients with early lung cancer. A nurse navigator tracks time to treatment.
- **Real people.** His wife appears by name only in the claims (CLM-0007); his daughters are not named. No relative is given a decision, a statement or a health fact in the modern episode, and the health care agent is unnamed. His coaches appear only in the claims. The president of the 1930s and other figures with records in the dataset are not named. The historical physicians named in the clippings are not named in the record.
